Medtronic closes 1st phase of Symplicity renal denervation feasibility trial

Medtronic

Medtronic (NYSE:MDT) said it’s closed the 1st phase of a feasibility trial for its next-generation Symplicity renal denervation device for high blood pressure.

The 9-patient trial delivered a 100% acute success rate in accessing the renal arteries and delivering the therapy, according to a press release.

"We look forward to moving forward with our clinical evaluation of this next-generation system that aims to augment our portfolio by offering more sophisticated features that should benefit both physicians and patients," Medtronic’s president of coronary & renal denervation Sean Salmon said in prepared remarks. "This feasibility study represents Medtronic’s commitment to providing physicians with a broader range of solutions for performing renal denervation and to collaborating with physician partners in the ongoing evaluation of this ground-breaking therapy."

Sign up to get our free newsletters delivered straight to your inbox

Earlier this week, the Fridley, Minn.-based medical device company touted the launch of another renal denervation trial, testing the Symplicity system against drug therapy alone in patients in Japan.

In September, Medtronic said an analysis of its Symplicity HTN 2 trial showed that the procedure is a cost-effective way to treat resistant hypertension.

And at the ACC conference in March, Medtronic unveiled other results from 2 trials of the Symplicity system. In a series of pilot studies including 153 Australian patients, researchers found that the device proved safe and effective after 3 years, with an average blood pressure reduction of -33/-19 Hg. There was no evidence of renal impairment, no hospitalizations due to hypotension and no procedure-related serious adverse events, according to a press release.

Perhaps most significant was that patients in the pilot studies who didn’t respond early in the trial became responders over time, with 100% of patients responding to renal denervation therapy by the 3-year mark.

"The sexiest message is the fact that the non-responders are responding over time," ACC program co-chair Dr. George Bakris said at the time. "Nobody understands why, but it’s definitely a huge novel finding in terms of better understanding what this whole thing is doing. We are learning as we go."

A 2nd randomized study of 106 patients found similar results of -32/-12 Hg blood pressure reduction after 1 year among patients receiving renal denervation, with no significant decline in kidney function and no late vascular complications. 

RSS From Medical Design & Outsourcing

  • LPKF defends LDS patent in Federal Patent Court
    Garbsen-based laser specialist LPKF today announced that it has won another key victory in the legal dispute with Motorola concerning the infringement of the patent for Laser Direct Structuring (LDS) developed by LPKF. A year ago, a lower court ruled in favor of LPKF in the patent infringement suit brought by LPKF against Motorola. Motorola […]
  • A-Laser helps Cardica produce next-generation medical devices
    Cardica, a designer and manufacturer of proprietary stapling and automated anastomotic devices for cardiac and laparoscopic surgical procedures, has partnered with precision laser-cutting and engineering firm, A-Laser, to expand and refine its line of next-generation medical devices. “For several years, we have worked with A-Laser on a number of product prototypes as well as ongoing […]
  • Procyrion CEO discusses its life-changing pump designed to heal the heart
    Ben Hertzog is the CEO of Procyrion, a Houston-based company that is developing Aortix, a custom designed pump built around a powerful micro-motor mounted on a set of expandable struts. Aortix is designed to rest and heal the heart by reducing afterload and improving blood flow to vital organs. Unlike other circulatory assist devices that […]
  • U.S. Based Qure Medical Acquires UK-Headquartered Silicone Altimex
    Qure Medical, with corporate headquarters in Twinsburg, Ohio, has acquired UK-headquartered Silicone Altimex, announced Randy Ross, President and CEO of Qure Medical. Financial terms of the agreement were not disclosed. Qure Medical provides integrated elastomer solutions to medical device manufacturers. Silicone Altimex is one of Europe’s leading independent manufacturers of cleanroom-produced silicone tubing components and […]
  • Coatings2Go is issued U.S. Patent for hydrophilic coating
    Coatings2Go, a medical device coating supplier, recently announced its receipt of a patent as it relates to hydrophilic coatings. The U.S. Patent Office has issued to Coatings2Go a patent with a grant date of July 14, 2015: U.S. Patent Number 9,080,061, “Coating Resins And Coatings With Multiple Crosslink Functionalities.” “This new patent is the third […]
  • Herrmann Ultrasonics, Inc. announces its 25 Year Anniversary
    In 1990, Thomas Herrmann, the son of Walter Herrmann, who founded Herrmann Ultraschalltechnik GmbH in 1961, established Herrmann Ultrasonics Inc. in the Chicago area. Hermann Ultrasonics, Inc. is proud to recognize a milestone year in observance of their 25th anniversary. Herrmann Ultrasonics has been focused on providing ultrasonic welding technology for various markets such as […]
  • Consumer Health Applications receive the most attention today, but the future is elsewhere
    Wearables for health fall into a wide range of technologies, functions, use cases and over-arching regulatory frameworks that developers and prospective entrants have to understand in order to effectively compete. Using an underlying taxonomy for human health, we establish a health-focused wearables taxonomy around three major categories—applications, use cases, and form factors—the three areas critical […]
  • Paralyzed men move legs with new non-invasive spinal cord stimulation
    Five men with complete motor paralysis were able to voluntarily generate step-like movements thanks to a new strategy that non-invasively delivers electrical stimulation to their spinal cords, according to a new study funded in part by the National Institutes of Health. The strategy, called transcutaneous stimulation, delivers electrical current to the spinal cord by way […]
  • SCHURTER’s new power entry module offers IP 54 protection with V-Lock cord sets
    SCHURTER is pleased to announce, that its power entry module, series 5707, now offers IP 54 protection with V-Lock cord sets at the power input, in addition to IP 65 protection to the equipment. The sealed module is ideal for use in medical equipment exposed to leaks, drips and spills, as well as equipment subject […]
  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]

Leave a Reply